Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493 obese participants (mean BMI of 37 kg\/m\u00b2).<\/p>\n
In 2025, Genentech and Roche entered<\/a> into an agreement with Zealand Pharma to co-develop and co-commercialize petrelintide for obesity.<\/p>\n Zealand Pharma received an upfront payment of $1.65 billion. It is also eligible for development milestones of $1.2 billion and sales-based milestones of $2.4 billion.<\/p>\n The study met its primary endpoint.<\/p>\n Once-weekly subcutaneous injections of petrelintide (escalated every fourth week ) showed statistically significant and clinically meaningful weight loss<\/a> from baseline after 28 weeks in all five treatment arms compared to placebo.<\/p>\n Roche\/Zealand Partnered Obesity Drug Achieves 11% Weight Loss<\/p>\n Petrelintide demonstrated<\/a> a favorable tolerability profile comparable to placebo, and the study observed no unexpected safety signals.<\/p>\n In patients with the highest reduction in body weight, 98% of petrelintide-treated participants reached the maintenance dose.<\/p>\n Accordingly, body weight reduction using the treatment regimen estimand was largely consistent with the efficacy estimand.<\/p>\n Favorable Safety Profile<\/p>\n Petrelintide demonstrated a favorable tolerability profile comparable to placebo. No unexpected safety signals were observed.<\/p>\n The treatment discontinuation rate due to adverse events was 4.8% with petrelintide in the maximally effective treatment arm versus 4.9% with placebo.<\/p>\n Gastrointestinal-related events were the most frequently reported adverse events, mostly being mild.<\/p>\n Across petrelintide treatment arms, 8.4% of participants withdrew from the trial for any reason, compared with 13.6% in the placebo group.\u00a0<\/p>\n Coming Up Next For Roche\u2019s Obesity Drug<\/p>\n Researchers will present the final ZUPREME-1 data at an upcoming medical congress. The findings will inform optimal Phase 3 designs and settings to evaluate petrelintide.<\/p>\n The second Phase 2 ZUPREME-2 trial of petrelintide versus placebo for obesity and type 2 diabetes is expected to deliver topline results in the second half of 2026.<\/p>\n The company will initiate a Phase 2 trial exploring the combination of petrelintide and CT-388 later in 2026.<\/p>\n In January, Roche released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity<\/a>.<\/p>\n The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) produced weight loss of 22.5% without reaching a weight-loss plateau at 48 weeks.<\/p>\n Price Action<\/p>\n